Business Context and Reporting Period
Company: Nano Dimension Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: February 2017 (Report No. 2)
Date of Filing: February 13, 2017
This filing incorporates by reference a press release announcing the formation of a new 3D bio-printing subsidiary focused on kidney diseases. The filing also incorporates specific sections of the press release into the company's registration statement on Form S-8.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notification of a corporate strategic action rather than a financial results report.
Material Changes
- Strategic Expansion: Nano Dimension announced the formation of a new subsidiary dedicated to 3D bio-printing.
- Focus Area: The new subsidiary will specifically target kidney diseases.
Guidance, Outlook, and Risks
The filing incorporates the "Forward Looking Statements" section from the February 13, 2017 press release into the Form S-8 registration statement. The text does not detail specific financial guidance, management commentary on performance, or a comprehensive list of risks within the body of this specific Form 6-K, deferring to the attached press release for those details.
Investor Verification Checklist
- Verify the full text of the press release titled "Nano Dimension to Form a 3D Bio-Printing Subsidiary to Focus on Kidney Diseases" for detailed operational plans.
- Review the "Forward Looking Statements" section incorporated into Form S-8 (File No. 333-214520) for associated risks and assumptions.
- Confirm the capital structure and funding requirements for the new subsidiary, as these are not detailed in this filing.